Table 4.
Summary of meta-analysis results in the achievement of the virological outcome by Pegylated interferon α-2a and α-2b plus ribavirin in patients with genotype 1 chronic hepatitis C
| Outcomes | N° of studies |
N° of patients |
N° and (%) of events |
RR (efficacy) | 95% CI (efficacy) | p |
Heterogeneity test |
|---|---|---|---|---|---|---|---|
| α-2a/α-2b | α-2a/α-2b | (Q;p;I2,%) | |||||
| Rapid Virological Response |
4 [17-19,22] |
1,374/1,355 |
186(13.5)/174(12.8) |
1.05 |
0.87–1.27 |
0.62 |
3.8;0.28;21.1 |
| Early Virological Response |
5[17-19,21,22] |
1,395/1,371 |
649(46.5)/572(38.4) |
1.12 |
1.03–1.22 |
0.011 |
7.58;0.14;42.8 |
| End of Treatment Response |
5[16,18,19,21,22] |
1,243/1,217 |
782(62.9)/627(51.5) |
1.22 |
1.14–1.31 |
<0.0001 |
7.6;0.11;47.3 |
| 5*[16,18,19,21,22] |
921/879 |
544(59)/403(45.8) |
1.29 |
1.18–1.41 |
<0.0001 |
8.37;0.08;52.1 |
|
| Sustained Virological Response | 6[16,18-22] |
1,336/1,310 |
574(43)/521(39.8) |
1.08 |
0.99–1.18 |
0.098 |
9.97;0.08;49.8 |
| 6**[16,18-22] |
1,058/732 |
473(44.7)/306(41.8) |
1.08 |
0.97–1.20 |
0.19 |
10.9;0.053;54.2 |
|
| 6*[16,18-22] | 1,014/972 | 406(40)/346(35.5) | 1.13 | 1.01–1.26 | 0.04 | 8.59;0.13;41.8 |